Clinical Significance Of Baseline And Post-Treatment CXCR1 Expression In Women With Breast Cancer Having Received...

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Neoadjuvant chemotherapy is a standard treatment for breast cancer.
• Understanding biomarkers that predict treatment response is crucial for personalized medicine.
• Chemokine receptor type 1 (CXCR1) plays a role in immune cell trafficking and may influence tumor microenvironment and treatment outcomes.

Purpose of the Study:

• To investigate the expression of chemokine receptor type 1 (CXCR1) in breast cancer tissues.
• To assess the relationship between CXCR1 expression and pathological response to neoadjuvant chemotherapy.
• To explore the association of CXCR1 with other clinical variables in breast cancer patients.

Main Methods:

• A prospective study involving 100 female breast cancer patients undergoing neoadjuvant chemotherapy.
• Immunohistochemical staining of tumor specimens to quantify CXCR1 expression.
• Analysis of baseline and post-treatment CXCR1 levels in relation to treatment response and clinical data.

Main Results:

• Patients with marked response to chemotherapy (Group A) had significantly lower baseline and post-treatment CXCR1 expression compared to those with mild/moderate response (Group B).
• Higher baseline CXCR1 expression was observed in patients with tumor grade 3 compared to grade 2.
• Multivariate analysis identified age, baseline CXCR1, and post-treatment CXCR1 as predictors of treatment response.

Conclusions:

• Baseline and post-treatment chemokine receptor type 1 (CXCR1) expression is associated with pathological response to neoadjuvant chemotherapy in breast cancer.
• CXCR1 may serve as a predictive biomarker for neoadjuvant chemotherapy response in breast cancer patients.